SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Clements PJ, Furst DE. Systemic sclerosis. Baltimore: Williams & Wilkins; 1995.
  • 2
    Poole JL, Steen VD. The use of Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res 1991; 4: 2731.
  • 3
    Steen VD, Medsger TA jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patient over time. Arthritis Rheum 1997; 40: 198491.
  • 4
    Silman A, Akesson A, Newman J, Henriksson H, Sandquist G, Nihill M, et al. Assessment of functional ability in patients with scleroderma: a proposed new disability assessment instrument. J Rheumatol 1998; 25: 7983.
  • 5
    Ruof J, Bruhlmann P, Stucki. Development and validation of a self-administered Systemic Sclerosis Questionnaire (SySQ). Rheumatology 1999; 38: 53542.
  • 6
    Stewart AL, Greenfield S, Hays RD, Wells KB, Rogers WH, Berry SD, et al. Functional status and well-being of patients with chronic condition: results from the Medical Outcomes Study. JAMA 1989; 262: 90713.
  • 7
    Stewart AL, Hays RD, Ware JE Jr. The MOS short-form general health survey: reliability and validity in a patients population. Med Care 1988; 26: 72435.
  • 8
    Ware JE Jr, Sherbourne CD. The MOS 36-item short-form survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 47383.
  • 9
    Nilsdotter AK, Roos EM, Westerlund JP, Roos HP, Lohmander LS. Comparative responsiveness of measures of pain and function after total hip replacement. Arthritis Rheum 2001; 45: 25862.
  • 10
    Goorman SD, Watanabe TK, Miller EH, Perry C. Functional outcome in knee osteoarthritis after treatment with hylan G-F 20: a prospective study. Arch Phys Med Rehabil 2000; 81: 47983.
  • 11
    Birrell FN, Hassell AB, Jones PW, Dawes PT. How does the short form 36 health questionnaire (SF-36) in rheumatoid arthritis (RA) relate to RA outcome measures and SF-36 population values: a cross-sectional study. Clin Rheumatol 2000; 19: 1959.
  • 12
    Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B, et al, Leflunomide Rheumatoid Arthritis Investigators Group. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Arthritis Rheum 2000; 43: 50614.
  • 13
    Thomas E, Hay EM, Hajeer A, Silman AJ. Sjogren's syndrome: a community-based study of prevalence and impact. Br J Rheumatol 1998; 37: 106976.
  • 14
    Strombeck B, Ekdahl C, Manthorpe R, Wikstrom I, Jacobsson L. Health-related quality of life in primary Sjogren's syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF 36. Scand J Rheumatol 2000; 29: 208.
  • 15
    Friedman AW, Alarcon GS, McGwin G Jr, Straaton KV, Roseman J, Goel N, et al, LUMINA Study Group: Lupus in Minority Populations, Nature versus Nurture. Systemic lupus erythematosus in three ethnic groups. IV. Factors associated with self-reported functional outcome in a large cohort study. Arthritis Care Res 1999; 12: 25666.
  • 16
    Stoll T, Gordon C, Seifert B, Richardson K, Malik J, Bacon PA, et al. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus. J Rheumatol 1997; 24: 160814.
  • 17
    Da Costa D, Dobkin PL, Fitzcharles MA, Fortin PR, Beaulieu A, Zummer M, et al. Determinants of health status in fibromyalgia: a comparative study with systemic lupus erythematosus. J Rheumatol 2000; 27: 36572.
  • 18
    LeRoy EC, Black C, Fleishmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (SSc): classification, subsets, and pathogenesis. J Rheumatol 1998; 15: 2015.
  • 19
    Apoloni G, Mosconi P, Ware JE Jr. Questionario sullo stato di salute SF 36: manuale d'uso e guida all'interpretazione dei risultati. Milano: Guerini e Associati; 1997.
  • 20
    Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 12815.
  • 21
    Wells AU, Hansell DM, Corrin B, Harrison NK, Goldstraw P, Black CM, et al. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax 1992; 47: 73842.
  • 22
    Matucci Cerinic M, Jaffa A, Kahaleh BM. Angiotensin converting enzyme: an in vivo and in vitro marker of endothelial injury. J Lab Clin Med 1992; 120: 42833.
  • 23
    Pignone A, Generini S, Matucci Cerinic M. Prostaglandin E1 restores the levels of vWF and ACE in chronic critical limb ischemia in systemic sclerosis. Clin Exp Rheumatol 2001; 19: 3589.
  • 24
    Lori S, Matucci Cerinic M, Casale R, Generini S, Lombardi A, Pignone A, et al. Peripheral neuropathy in systemic sclerosis: the median nerve as a target structure. Clin Exp Rheumatol 1996; 14: 6015.
  • 25
    Pignone A, Scaletti C, Matucci Cerinic M, Vazquez-Abad D, Del Papa N, Meroni PL, et al. Antiendothelial cell antibodies in systemic sclerosis: correlation with vascular involvement. Clin Exp Rheumatol 1998; 16: 5727.
  • 26
    Clark PE, Schover LR, Uzzo RG, Hafez KS, Rybicki LA, Novick AC. Quality of life and psychological adaptation after surgical treatment for localized renal cell carcinoma: impact of the amount of remaining renal tissue. Urology 2001; 57: 2526.
  • 27
    Janda M, Gerstner N, Obermair A, Fuerst A, Wachter S, Dieckmann K, et al. Quality of life changes during conformal radiation therapy for prostate carcinoma. Cancer 2000; 89: 13228.
  • 28
    Forjaz MJ, Guarnaccia CA. Hematological cancer patients' quality of life: self versus intimate or non-intimate confidant reports. Psychooncology 1999; 8: 54652.
  • 29
    Angermann CE, Bullinger M, Spes CH, Zellner M, Kemkes BM, Theisen K. Quality of life in long-term survivors of orthotopic heart transplantation. Z Kardiol 1992; 81: 4117.
  • 30
    Stull DE, Starling R, Haas G, Young JB. Becoming a patient with heart failure. Heart Lung 1999; 28: 28492.
  • 31
    Moser DK, Clements PJ, Brecht ML, Weiner SR. Predictors of psychosocial adjustment in systemic sclerosis: the influence of formal education level, functional ability, hardiness, uncertainty, and social support. Arthritis Rheum 1993; 36: 1398405.
  • 32
    Roca RP, Wigley FM, White B. Depressive symptoms associated with scleroderma. Arthritis Rheum 1996; 39: 103540.
  • 33
    Angelopoulos NV, Drosos AA, Moutsopoulos HM. Psychiatric symptoms associated with scleroderma. Psychother Psychosom 2001; 70: 14550.